ClinicalTrials.gg
RecruitingNCT07712783Updated Oct 30, 2026

Lateral QL Block vs Intrathecal Morphine for Cesarean Section

An interventional study of Lateral Quadratus Lumborum Block and ıv morphine PCA in Anesthesia, Postoperative Pain and Regional Anesthesia, sponsored by Ondokuz Mayıs University. Recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Ondokuz Mayıs University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Pain, Postoperative by Ondokuz Mayıs University — 8 open to participants now, 8 under way, none of them phase 3. Pain, Postoperative · Ondokuz Mayıs University.

Planned enrollment
20th of 24
56 · median 69
Started
2026
with 7 others
No phase
24 of 29
8 open now
Registered
25th of 29
by date

Among the 29 studies in Pain, Postoperative by Ondokuz Mayıs University, this one is the 20th largest by planned enrollment of the 24 interventional ones that give a count, is one of 8 that started in 2026, is one of 24 with no phase, and was the 25th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

8 of the 29 studies in Pain, Postoperative by Ondokuz Mayıs University are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Pain, Postoperative by Ondokuz Mayıs University, or all of them as a file.
02

Study summary

Effective postoperative analgesia after cesarean delivery is essential for maternal recovery, early mobilization, breastfeeding, and maternal-infant bonding. Although intrathecal morphine (ITM) is considered the gold standard for post-cesarean analgesia, its use is associated with opioid-related adverse effects. Ultrasound-guided lateral quadratus lumborum block (QLB-I) has emerged as a promising alternative. This randomized, double-blind, non-inferiority trial aims to compare the postoperative analgesic efficacy of lateral QLB-I with ITM. Secondary outcomes include postoperative opioid consumption, pain scores, opioid-related adverse effects, quality of recovery (ObsQoR-11T), and maternal satisfaction.

Read the detailed description

Effective postoperative analgesia following cesarean delivery is essential not only for improving maternal comfort but also for facilitating early mobilization, breastfeeding, and maternal-infant bonding. Inadequate pain control has been associated with delayed mobilization, pulmonary complications, postpartum depression, and the development of chronic postsurgical pain (CPSP).

Intrathecal morphine (ITM) has long been regarded as the gold standard for post-cesarean analgesia, providing effective pain relief for 18-24 hours after a single dose. However, its use is limited by opioid-related adverse effects, including pruritus, postoperative nausea and vomiting (PONV), sedation, and urinary retention. These adverse effects may reduce maternal satisfaction and negatively affect breastfeeding and early mobilization.

In recent years, quadratus lumborum block (QLB) has emerged as an effective alternative for postoperative analgesia in abdominal surgery. Among the various QLB approaches, the lateral QLB-I technique has attracted considerable interest because of its ease of ultrasound-guided application, low incidence of motor block, and potential to provide extensive visceral and somatic analgesia. Previous studies have demonstrated that QLB can effectively attenuate both somatic and visceral pain, with cranial spread of local anesthetic along the thoracolumbar fascia reaching the ventral rami of the thoracic nerves (Blanco, 2015; Elsharkawy, 2019).

Randomized controlled trials in patients undergoing cesarean delivery have shown that QLB reduces postoperative opioid consumption, lowers pain scores, and improves patient satisfaction compared with control groups (Salama, 2020; Zhu, 2021). However, studies directly comparing QLB with ITM remain limited. Current evidence suggests that the analgesic efficacy of QLB may be comparable to that of ITM, although robust evidence demonstrating non-inferiority is still lacking.

Compared with ITM, the principal advantages of lateral QLB include the absence of motor blockade, the potential to reduce opioid-related adverse effects, and facilitation of early mobilization. Although ITM provides potent analgesia, demonstrating that the analgesic efficacy of lateral QLB is clinically equivalent within a non-inferiority margin not exceeding 10 mg intravenous morphine milligram equivalents (IV-MME) would represent a clinically acceptable outcome in terms of patient comfort and safety.

Accordingly, the primary objective of this study is to determine whether lateral QLB-I provides non-inferior postoperative analgesia compared with ITM. Secondary objectives include a comprehensive evaluation of adverse effects, quality of recovery using the ObsQoR-11T, and postoperative opioid consumption.

03

Conditions studied

  • Anesthesia
  • Postoperative Pain
  • Regional Anesthesia

Browse trials for

Keywords

  • cesarean delivery
  • postoperative opioid consumption
  • postoperative pain
  • lateral quadratus lumborum block
  • intrathecal morphine
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged between 18 and 45 years.
  • Singleton term pregnancy (≥37 weeks of gestation).
  • (ASA) physical status II.
  • Scheduled to undergo elective cesarean delivery via a Pfannenstiel incision.
  • Planned to receive spinal anesthesia for cesarean delivery.
  • Provision of written following a comprehensive explanation of the study.
  • Sufficient cognitive capacity to understand and complete the study assessment instruments, including the Numeric Rating Scale (NRS) and the ObsQoR-11T.

Exclusion criteria

Exclusion Criteria:

  • Known allergy or to any of the study medications, including morphine, bupivacaine, or fentanyl.
  • Coagulopathy ( [INR] >1.5 or count \<100,000/mm³).
  • Current treatment with anticoagulant or antiplatelet agents (e.g., heparin, low-molecular-weight heparin, or aspirin >100 mg/day).
  • Infection, hematoma, or skin lesion at the planned block insertion site.
  • Diagnosis of preeclampsia, eclampsia, or HELLP syndrome.
  • Placenta previa, placenta accreta spectrum, or placental abruption.
  • Gestational diabetes mellitus or chronic hypertension.
  • Emergency cesarean delivery indicated because of fetal distress.
  • Conversion to general anesthesia during cesarean delivery.
  • History of chronic pain syndrome (e.g., fibromyalgia, lumbar disc herniation, or neuropathic pain).
  • Regular use of opioids or psychotropic medications within the preceding 3 months.
  • Diagnosis of epilepsy, severe anxiety disorder, or major depressive disorder.
  • Obesity ( >35 kg/m²).
  • Severe systemic disease, including (NYHA) class III or IV heart failure, hepatic or renal failure, advanced respiratory disease, or obstructive sleep apnea.
  • Advanced pulmonary disease requiring continuous positive airway pressure (CPAP) therapy.
  • Inadequate spinal anesthesia or the requirement for supplemental intraoperative analgesia.
  • Surgical duration exceeding 120 minutes.
  • Excessive intraoperative blood loss (≥1,000 mL) or the need for blood transfusion.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (estimated)

Study arms

  • Experimental
    Group QLB

    LQLB (Active) + Sham ITM

    Procedure: Lateral Quadratus Lumborum Block · Drug: ıv morphine PCA

  • Experimental
    Group ITM

    ITM (Active) + Sham QLB

    Drug: ıv morphine PCA · Procedure: Intrathecal morphine

Interventions

  • ProcedureLateral Quadratus Lumborum Block

    Active Lateral QLB Local anesthetic: 0.25% bupivacaine, 0.4 mL/kg perside (maximum 30 mL per side). Maximum total dose: Bupivacaine ≤2.5 mg/kg (maximum approximately 150 mg). Timing: Immediately after completion of surgery. The patient will be positioned supine or in a slight lateral decubitus position. A high-frequency linear US transducer (5-12 MHz) will be placed on the anterolateral abdominal wall at the T12-L1 level. The fascial plane will be identified under ultrasound guidance. A 22-gauge, 100-mm needle will be advanced using an in-plane approach, and after negative aspiration, the local anesthetic will be injected incrementally with hydrodissection confirming correct spread. Sham ITM: The spinal anesthesia technique will be identical to that of the active ITM group. Morphine will be replaced with 0.2 mL preservative-free normal saline, while maintaining an identical syringe volume (2.7 mL) and appearance.

    Also known as: Lateral QLB

  • Drugıv morphine PCA

    A standardized IV PCA protocol will be initiated for all patients using a PCA device (Body Guard 575 pain manager, UK), programmed to deliver morphine boluses of 0.01-0.015 mg/kg (IBW), with a 6-minute lockout and a 4-hour maximum dose of 0.1-0.15 mg/ kg (IBW). No basal infusion will be used.

    Also known as: PCA

  • ProcedureIntrathecal morphine

    Hyperbaric 0.5% bupivacaine 12.5 mg, fentanyl 20 µg, and morphine 80 µg (0.08 mg). Spinal anesthesia will be performed at the L3-L4 or L4-L5 intervertebral space using a 25-gauge Quincke spinal needle. The study solution will be prepared to a total volume of 2.7 mL. Sham QLB Following completion of surgery, the patient will be positioned in the lateral decubitus position. The ultrasound transducer will be placed over the lateral QLB scanning window. A 22-gauge needle will be advanced into the skin and subcutaneous tissue only, without entering the fascial plane. To maintain procedural standardization and preserve blinding, 1-2 mL of normal saline will be injected into the subcutaneous tissue. Procedure duration, patient positioning, ultrasound probe placement, and dressing application will be identical to those used for the active lateral QLB-I procedure. A sterile dressing will be applied at the end of the procedure.

    Also known as: ITM

06

What researchers measure

Primary outcomes

  1. Cumulative equivalent morphine consumption in the first 24 hours after surgery

    The total dose of morphine administered via the patient-controlled analgesia (PCA) device, together with all rescue opioids administered during the first 24 postoperative hours following surgery, will be converted to morphine milligram equivalents (MME) using validated conversion factors and summed.

    Time frame: postoperative day 1

Secondary outcomes

  1. Cumulative equivalent morphine consumption in the first 48 hours after surgery

    The total dose of morphine administered via the patient-controlled analgesia (PCA) device, together with all rescue opioids administered during the first 48 postoperative hours following surgery, will be converted to morphine milligram equivalents (MME) using validated conversion factors and summed.

    Time frame: postoperative day 2

Other outcomes

  1. Cumulative equivalent morphine consumption in the first 12 hours after surgery

    The total dose of morphine administered via the patient-controlled analgesia (PCA) device, together with all rescue opioids administered during the first 12 postoperative hours following surgery, will be converted to morphine milligram equivalents (MME) using validated conversion factors and summed.

    Time frame: postoperative day 1

  2. Postoperative pain scores

    Pain status at rest and while activity will be assessed by NRS score at 0, 3, 6, 12, 24,36 and 48. hours after surgery. The NRS is an 11-point numeric scale that ranges from 0 to 10.

    Time frame: postoperative day 2

  3. area under the NRS score curve (AUC) for resting

    area under the NRS score curve (AUC) for resting and active 48 hours after surgery

    Time frame: postoperative day 2

  4. Integrated Analgesic Score

    Composite outcome integrating pain burden (AUC) and opioid consumption (IV-MME), expressed as the Integrated Analgesia Score (IAS), with lower scores indicating better overall analgesic efficacy.

    Time frame: postoperative day 2

  5. Effective Analgesic Score

    The Integrated Analgesia Score (IAS) will be calculated by jointly evaluating the mean pain scores (NRS, 0-10) and cumulative intravenous morphine milligram equivalent (IV-MME, mg) consumption over the 0-48-hour postoperative period.

    Time frame: postoperative day 2

  6. Time of first analgesic request

    Time at which the first analgesic is requested

    Time frame: postoperative day 1

  7. The number of patients requiring rescue analgesics

    The number of patients requiring rescue analgesics will be recorded over 24 hours.

    Time frame: postoperative day 1

  8. ObsQoR-11T (Obstetric Quality of Recovery) score

    A validated patient-reported outcome measure assessing the quality of postoperative recovery after cesarean delivery. The questionnaire consists of 11 items evaluating pain, physical comfort, physical independence, emotional state, and the ability to care for the newborn, with higher scores indicating better quality of recovery. Scores range from 0 to 110, with higher scores indicating better recovery. Assessments will be performed preoperatively (baseline) and at 24 and 48 hours postoperatively.

    Time frame: postoperative day 2

  9. The number of patients requiring postoperative antiemetics.

    The number of patients requiring treatment and PONV scores will be recorded in the post-anesthesia care unit (PACU) and at 3, 6, 12, 24, 36, and 48 hours postoperatively. PONV will be assessed using a 4-point scale: 0 = no nausea or vomiting; 1 = mild nausea; 2 = one episode of vomiting; and 3 = more than one episode of vomiting.

    Time frame: postoperative day 2

  10. The incidences of post-operative pruritus

    The presence and severity of pruritus will be assessed using a four-point scale where 0 indicates no pruritus, 1 indicates mild pruritus, 2 indicates moderate pruritus, and 3 indicates severe pruritus. A score of ≥1 will be considered the presence of pruritus.

    Time frame: postoperative day 2

  11. Sedation score

    Sedation levels will be assessed using the Pasero Opioid-Induced Sedation Scale (POSS) and recorded during the first 48 postoperative hours in the post-anesthesia care unit (PACU) and at 3, 6, 12, 24, 36, and 48 hours postoperatively. Sedation will be graded as follows: S = awake and alert; 1 = slightly drowsy, easily aroused; 2 = frequently drowsy, easily aroused, drifts off to sleep during conversation; 3 = somnolent, difficult to arouse; and 4 = minimal or no response to verbal or physical stimulation. Opioid-induced sedation will be defined as a POSS score ≥3 or a respiratory rate \<8 breaths/min.

    Time frame: postoperative day 2

  12. The incidences of Urinary retention

    Number of patients with urinary retention (defined as failure to achieve spontaneous voiding within 8 hours after Foley catheter removal)

    Time frame: postoperative day 2

  13. The morbidity of patients

    The patients comorbidities will be assessed using the Charlson Comorbidity Index

    Time frame: Postoperative 1 month on an average

  14. The number of patients with complications

    The number of patients has any complications -directly related to the block or the drug used in the block- will be recorded

    Time frame: Postoperative 1 month on an average

  15. Delayed onset of lactation

    Delayed onset of lactation will be defined as the maternal report of milk coming in (based on subjective breast fullness and the transition from colostrum to mature milk) occurring more than 48 hours after delivery.

    Time frame: postoperative day 2

  16. Apgar scores

    Apgar scores at 1 and 5 minutes will be recorded. In addition, the need for neonatal intensive care unit (NICU) admission and any requirement for additional neonatal resuscitation will be documented.

    Time frame: postoperative day 1

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 5 months is below that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: primary completion Sep 2026 → Jan 2027 and completion Dec 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 17, 2026
StartActual
Jul 15, 2026
Primary completionEst.
Jan 1, 2027was Sep 2026
CompletionEst.
Mar 1, 2027was Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
Ondokuz Mayis University is now Recruiting
Oct 30, 2026
Primary completion
Sep 1, 2026→Jan 1, 2027
Oct 30, 2026
Study completion
Dec 1, 2026→Mar 1, 2027
Oct 30, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Ondokuz Mayis University · Samsun, Turkey (Türkiye)Contact added b•••@hotmail.com · •••2493
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    Ondokuz Mayis University is now Recruiting
    Primary completion Sep 1, 2026→Jan 1, 2027
    Study completion Dec 1, 2026→Mar 1, 2027
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Ondokuz Mayis University · Samsun, Turkey (Türkiye)Contact added b•••@hotmail.com · •••2493
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07712783
Responsible party
BURHAN DOST (Director, Ondokuz Mayıs University) — Principal investigator
First posted
Jul 17, 2026
Start date
Jul 15, 2026
Primary completion
Jan 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Burhan Dost
Contact
burhandost@hotmail.com
+903623121919
Esra Turunc
Contact
esra.kiymaz.ek@gmail.com
+903623121919
Burhan Dost
principal investigator · Ondokuz Mayıs University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion